{"id":293042,"date":"2025-08-18T00:00:00","date_gmt":"2025-08-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0002-2024-biopharma-alzheimers-disease-access-reimbursement-access-reimbursement\/"},"modified":"2026-04-22T05:10:51","modified_gmt":"2026-04-22T05:10:51","slug":"acrecg0002-2025-biopharma-alzheimers-disease-access-reimbursement-access-reimbursement-alzheimers-disease-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0002-2025-biopharma-alzheimers-disease-access-reimbursement-access-reimbursement-alzheimers-disease-us\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Alzheimer&#8217;s Disease (US)"},"content":{"rendered":"<p>Eisai \/ Biogen\u2019s Leqembi (lecanemab) and Eli Lilly\u2019s Kisunla (donanemab) are vying to capitalize on the potential for a disease-modifying therapy (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>) in Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>), and additional anti-<abbr title=\"beta-amyloid\">A\u03b2<\/abbr> monoclonal antibodies (<abbr title=\"monoclonal antibody\">MAb<\/abbr>s) (e.g., Roche\u2019s trontinemab) will drive competition and expand treatment choices for patients. Lundbeck \/ Otsuka\u2019s Rexulti became the first <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved drug to treat agitation in <abbr title=\"Alzheimer's disease\">AD<\/abbr>, and other novel therapies (i.e., Axsome\u2019s Auvelity) for this condition are advancing. Understanding neurologists\u2019 preferences and expectations for new therapeutics and payers\u2019 receptivity to high-priced brands in this underserved and heavily generic market is key for developers with agents in the large <abbr title=\"Alzheimer's disease\">AD<\/abbr> pipeline.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the state of coverage of Leqembi, Kisunla, Rexulti, and other <abbr title=\"Alzheimer's disease\">AD<\/abbr> brands? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists\u2019 prescribing?<\/li>\n<li>What coverage and uptake are expected for emerging therapies (i.e., Axsome\u2019s Auvelity, <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s KarXT, Roche\u2019s trontinemab, Eli Lilly\u2019s remternetug, Eisai \/ Biogen\u2019s <abbr title=\"subcutaneous\">SC<\/abbr> lecanemab, Novo Nordisk\u2019s semaglutide)? What clinical and nonclinical differentiators would drive preferential use and coverage terms?<\/li>\n<li>What is the state of coverage for <abbr title=\"Alzheimer's disease\">AD<\/abbr> diagnostics (e.g., <abbr title=\"beta-amyloid\">A\u03b2<\/abbr> <abbr title=\"positron emission tomography\">PET<\/abbr> scans, blood-based biomarkers), and how are physicians using them?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key drugs: <\/strong>Leqembi, Kisunla, Rexulti, Adlarity, Auvelity<\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Survey of 100 U.S. neurologists<\/li>\n<li>Survey of 30 U.S. managed care organization pharmacy and medical directors<\/li>\n<\/ul>\n<p><strong>Fingertip Formulary: <\/strong>Formulary coverage by Medicare Part D plans covering up to 37.5 million lives<\/p>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key analyses:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Reimbursement and contracting<\/li>\n<li>Access and prescribing<\/li>\n<li>Buy &#038; bill calculations and analysis<\/li>\n<li>Couponing and patient affordability<\/li>\n<li>Opportunities and challenges for emerging therapies<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-293042","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293042\/revisions"}],"predecessor-version":[{"id":575743,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293042\/revisions\/575743"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=293042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}